---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-033507"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:19:11.928948+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023

## Summary
- TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.
- Of 3 evaluable CIS patients, 1 heavily pre-treated BCG-unresponsive patient achieved complete response; tumor regression in other 2.
- ADVANCED-2 Phase 1b/2 trial to enroll up to 102 CIS patients (BCG-naïve and BCG-unresponsive) starting 2H2023.
- Company expects current resources to fund operations into 2025, supporting clinical plans.

## SEC filing metadata
- accession: 0001213900-23-033507
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/0001213900-23-033507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023033507/ea177564-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-033507
- JSON: https://secwatch.observer/filing/0001213900-23-033507.json
- Plain text: https://secwatch.observer/filing/0001213900-23-033507.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.